Smart Labels market Professional Survey Report by 2035 Pharmaceutical smart labels offer functionality and connectivity, along with providing an interactive and real-time solution, across the overall supply chain Roots Analysis has announced the addition of “Smart Pharmaceutical and Healthcare Labels Market, 2022-2035” report to its list of offerings. The report features an extensive study of the current market landscape and future opportunities associated with the smart pharmaceutical and healthcare labels, offering in-depth analyses of the various business entities engaged in this domain, across key global regions. Request a free sample of the report https://www.rootsanalysis.com/reports/smart-labels-market/request-sample.html Amongst other elements, the report includes:  A brief overview of smart labels, along with the information on their role and advantages in healthcare sector, along with details on the types of smart labels, featuring their applications in the pharmaceutical and healthcare domain. In addition, it includes a discussion on various challenges associated with the adoption of smart labels, future perspectives, and the factors driving the smart pharmaceutical and healthcare labels industry.  A detailed review of the overall landscape of players engaged in the smart pharmaceutical and healthcare label providers domain, along with information on type of technology, RFID frequency band and area(s) of application.  A detailed competitiveness analysis of companies engaged in the development of smart pharmaceutical and healthcare labels, based on their supplier strength, service strength and portfolio strength.  Elaborate profiles of prominent players that claim to specialize in offering smart pharmaceutical and healthcare labels. Each profile features a brief overview of the company, along with information on their year of establishment, number of employees, location of headquarters, key executives, as well as details related to their smart labels focused portfolio, recent developments and an informed future outlook.  An in-depth analysis of patents related to smart pharmaceutical and healthcare labels that have been filed / granted till date, based on several relevant parameters, such as type of patent, publication year, geographical location / patent jurisdiction, legal status, CPC symbols, type of industry, type of applicant and leading players (in terms of number of patents filed / granted). In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents filed / granted in this industry.  A detailed analysis of the partnerships and collaborations inked in the domain, during the period 2018-2022, based on several parameters, such as year of partnership, type of partnership, most active player and region.  A detailed analysis of the current and future market based on blue ocean strategy, covering a strategic plan / guide for emerging players in this domain to help unlock an uncontested market, featuring thirteen strategic tools that can help software developers to shift towards a blue ocean strategic market.  A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry's evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall smart pharmaceutical and healthcare labels market.  The financial opportunity within the smart labels market has been analyzed across the following segments:  Type of Technology  RFID  NFC  Other Technologies  Type of packaging  Primary Packaging  Secondary Packaging  Type of Primary Packaging  Vials  Syringes  Cartridges  Ampoules  Bottles  Blister Packs  Type of Secondary Packaging  Boxes  Cartons  Pouches  Key Geographical Regions  North America  Europe  Asia-Pacific  MENA  Latin America To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/smart-labels-market.html You may also be interested in the following titles: Cell Therapy Manufacturing Market Global TCR Therapy Market About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com Smart Labels Market, Smart Labels Market Growth, Healthcare Labels, Smart Labels, NFC

Exosome Therapeutics Market 2022 – Industry Growth by 2035 In recent years, therapies utilizing extracellular vesicles have garnered significant attention among the industry stakeholders for the treatment of diverse target indication, primarily owing to the various benefits offered by them, including target specificity, enhanced tissue regeneration, and reduced inflammation and chronic pain. Over time, various research studies have demonstrated the potential of exosomes (membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. As a result, exosome therapeutics domain has been gaining traction recently. INTRODUCTION TO EXOSOMES Exosomes are extracellular vesicles, which have endosomal origin and may contain different biomolecules, including proteins, DNA, lipids, miRNA or RNA, based on the type of cell of their origin and its conditions. Exosomes convey a wide range of information to the target cells, depending on their source. In addition, they are involved in regulating the expression of the targets that are linked to RNA as they can affect the expression of RNA. TYPES OF EXTRACELLULAR VESICLES Micro-vesicles have size of about 100 nm and are formed by direct outward budding of the plasma membrane. Their formation solely depends on the surrounding environment and this process requires the presence of cytoskeleton components, namely actin/ Exosomes have a diameter in the range between 30-150 nm and are formed by inward budding and get developed into the multivesicular bodies (MVBs). Owing to their long half-life, exosomes can target specific organs of the body, which makes them widely studied vesicles for immunological purposes. Apoptotic bodies have a diameter of about 5,000 nm and formed after the separation of plasma membrane from the skeleton. They can be easily distinguished from micro vesicles and exosomes because of their unscathed organelles as well as chromatin. EXOSOME BIOGENESIS, FORMATION, DEVELOPMENT AND SECRETION Exosomes are known to arise from the inward folding of multi-vesicular bodies (MVBs) in order to form the intraluminal vesicles (ILVs). These MVBs are then delivered to the trans-Golgi network (TGN) for the recovery of endosomes, which further move to lysosome for degeneration of the carried substances. The most essential component of exosome biogenesis is the formation of ESCRT. Formation and development of exosomes:  Sorting of internalized cargoes into early endosomes  Maturation into late endosomes or multivesicular bodies  Delivery of cargoes from trans-Golgi network and cytosol  Exosomes cargo in multivesicular bodies are transported to plasma membrane  Fusion with the plasma membrane  Secretion of exosomes ADVANTAGES AND FUTURE POTENTIAL OF EXOSOME THERAPEUTICS: Advantages:  High Compatibility: Exosomes are naturally occurring compounds that can withstand digestive enzymes.  Low Immunogenicity: Due to the innate properties of exosomes including their potential tissue of cell selectivity.  Targeted Drug Delivery: Ability to cross blood brain barrier cause lesser systemic effects and low toxicity. Future Potential:  Several emerging players have undertaken initiatives to explore the potential of exosomes for diagnosis of various diseases.  Application of exosomes as biomarker or vector of various potential therapeutic molecules, represents a theragnostic approach.  Advanced exosome technologies are being developed to fully substructure the potential therapeutic applications of exosomes. For additional details, please visit https://www.rootsanalysis.com/blog/introduction-to-exosome-therapeutics/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities The application of digital twins in healthcare has the potential to revolutionize patient care, improve clinical outcomes, and reduce costs. Digital twins, or virtual replicas of physical objects and environments, are being used in many different industries, and healthcare is no exception. In healthcare, these can be used to provide better patient monitoring, improve remote care, and create personalized treatments. What is a Digital Twin? Digital twins are virtual representations of real-world objects. A digital twin is a piece of equipment, for example, may have the same functionality as the physical counterpart. Digital twins can be created using a wide range of data sources, such as sensors, models, and images. In the context of healthcare, these technologies can include the full representation of a patient’s medical history, symptoms, current treatment, and even biometric data, such as blood pressure and heart rate. Benefits Associated with The Use of Digital Twins Digital twins offer many benefits to the healthcare industry. In the following sections, we explore the top three benefits offered by digital twin technologies. • Real-Time Data Access – While physical objects can be monitored and controlled, the data is often delayed. A digital twin, on the other hand, can be almost immediately updated with data. This means that healthcare providers can see and respond to real-time changes / real world evidence and abnormalities. • Improved Remote Care – Remote care is when healthcare is provided to patients who are not physically in a healthcare facility. Remote care is growing in popularity, but it comes with several challenges, such as a lack of real-time data and an inability to supervise the patient. Digital twins can help with these challenges by providing real-time data and allowing healthcare providers to view the patient remotely (telemedicine support). Disadvantages Associated with The Use of Digital Twins For all the benefits of digital twins, there are still some challenges that need to be addressed. In the following sections, we explore the top three challenges. • Difficulty in Adoption – Digital twins have been in use since the early 2000s, but they have only recently started to be used in healthcare. This is largely due to the fact that digital twins have been primarily used in industrial settings and that the concept has been hard for healthcare providers to grasp. While many find the concept of a digital twin attractive, it has been challenging for healthcare providers to adopt the concept. • Possibility of False Information – When data is fed into a digital twin, it can be inaccurate or incomplete. This can lead to incorrect findings and incorrect treatment plans. However, there are some efforts underway to solve this problem. One approach is to make the data used to create the digital twin as accurate as possible. Another approach is to let the digital twin correct itself based on new data. Future Perspectives In the following sections, we explore three ways in which the use of digital twins in healthcare can be improved. • Better Adoption Rates – With better adoption rates, healthcare providers will be able to use digital twins to their full potential. With the help of vendors and organizations, such as the Industrial Internet Consortium, healthcare providers can be better informed about the advantages of digital twins. Despite their immense rise in popularity, digital twins still have some issues that need to be resolved. As such, there are some ways in which the use of digital twins in healthcare can be improved. For additional details, please visit https://www.rootsanalysis.com/blog/digital-twins-in-healthcare/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Adeno-Associated Viral Vectors: Unlocking the Future Opportunities Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level, the demand for such therapies has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development. Further, various gene therapy developers have raised more than USD 10 billion capital during the year 2021. With the growing interest in such therapies, the demand for novel delivery vectors has also increased. Among various gene delivery vectors available, adeno-associated viral vectors have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors-based drugs, LUXTURNA® and ZOLGENSMA®. In order to cater to the demand, close to 100 players, across the globe, have emerged for the development and manufacturing of adeno-associated viral vectors. In fact, a number of these companies also offer advanced technology platforms, enabling the processing of AAV vectors and related therapies across different scales of operation. Various industry and non-industry players are actively engaged in research and development of novel gene delivery technologies, which are safe and effective. 155+ Clinical Trials have been / are being conducted The stakeholders have invested extensively in conducting clinical trials for evaluating the efficacy of the therapeutic candidates in the treatment of a variety of indications. ~4,300 Patent Filed / Granted in the Domain Examples of leading industry stakeholders, in terms of most patent applications filed include Genzyme, Voyager Therapeutics, REGENXBIO, Baxalta and Spark Therapeutics. 200+ Partnerships and Collaborations signed in the Domain The growing partnerships and collaborations signed between different stakeholders is indicative of the significant demand of vectors and related therapies from the past few years. As projected by Roots Analysis, oncological disorders therapeutic area will have majority share in the adeno-associated viral vector market. As projected by Roots Analysis, the overall market of AAV vector manufacturers market is expected to expand in the coming years. For additional details, please visit https://www.rootsanalysis.com/blog/adeno-associated-viral-vector/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Modular Construction – Retrofitting Conventional Buildings Shifting construction away from traditional sites and into factories could dramatically change the way we build. Will off-site builds bolster construction this time around? Over the years, construction has straggled behind other sectors in terms of efficiency. Off-site builds or modular construction is a powerful way to reform construction business saving more time, labor, cost and productivity mutually benefitting the manufacturer as well as the customer. What is Modular Construction? Modular Construction is a process in which different components known as Modules are constructed in a controlled factory setting and later assembled on the desired site as per the requirement of the user. In general, 60% to 90% of the work is completed offsite while the rest on the location where the facility is needed. The factory-made, standard modules are accustomed with walls, doors, ceilings, frames, and windows. Additionally, the modules can be integrated with more specific components, such as air handling units, fan filter units, air showers along with the lighting and plumbing facility intended for pharmaceutical use. It is worth mentioning, majority of the modular facilities built are GMP certified ensuring required quality standards have been met while construction. Types of Modular Construction Modular Construction can be broadly categorized into two categories, namely permanent and relocatable. Permanent modular builds mean the facilities are constructed to be used at the same location wherein it has been assembled. In other words, the building is similar to conventionally constructed infrastructure except the fact it has been built off-site. Need for Modular Facilities Conventional construction has never shown to surpass 80% mark owing to factors including logistical delays, type of material used, method of construction adopted and shortage of manpower eventually hampering the productivity. Whereas prefabricated approaches have reported to increase productivity by more than 100%. Modular construction acts as a sustainable method empowering today’s construction sector. The Modular Construction Process In the first phase, a description of the building that is to be constructed is created through discussion between the customer and modular building manufacturer followed by review of the engineering department to evaluate whether the proposed design meets all the applicable building codes. Then, granting of building permit is required in most jurisdictions for constructing new structures, or performing major renovations. Modular Construction in Pharmaceutical Industry The concept of modular construction has been used in other industries for a long time; however, over the past two to three decades, it has only gained significant attention within the pharmaceutical industry. Moreover, there is immense pressure on drug manufacturers to market novel drugs as soon as possible, before patent expiry. Increased pressure to expedite time to market, coupled with the need to decrease operating costs and increase manufacturing efficiencies, have amplified the value of smaller production facilities, which are more efficient and flexible. The modular construction market developments have made modular facilities more attractive to drug manufacturers today, as these facilities can quickly switch between multiple drugs, enabling formulation and packaging in multiple formats, such as solid, liquid, semi-solid and parenteral dosage forms. Roadblocks to Headway It is evident that shifting from conventional on-site construction to off-site modular construction can fundamentally avoid unforeseeable risks. However, on the other hand, construction of modular facilities may face certain challenges, in order to maintain the essentials of design and equipment of the facility. Some of the challenges with this approach may involve factors, such as logistics constraints, transportation, safety permits and communication barriers. For additional details, please visit https://www.rootsanalysis.com/blog/modular-construction-in-pharma-industry/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Long-Acting Drug Delivery: A Novel Pharmacological Strategy to Deliver Therapeutic Modalities LADD has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. These novel systems circumvent the limitations of conventional drug delivery system, such as multiple dosing frequency, fluctuating plasma levels, high toxicity levels and poor patient compliance. Principles and Strategies associated with Long-Acting Drug Delivery Lately, many technologies are being explored to develop long-acting drug in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The LADD technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery system. Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. What are the Benefits of Outsourcing to Contract Service Providers (CDMOs / CDOs / CMOs)? One of the critical factors associated with the development of long-acting drugs is the selection of drug therapeutic window and its absorption characteristics. It also encompasses the quantitative determination of drug metabolism and pharmacokinetic (DMPK) properties. In addition, the formulation of these drugs is a complex process, especially if there is inclusion of highly potent molecules. Some of the other challenges include aseptic manufacturing, terminal sterilization, suitable characterization methods, lack of GMP-certified facilities and specialized equipment. Owing to the advanced LADD technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability on stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome. Bottom Line Keeping every trend in mind, Roots Analysis has provided complete information on market trends in long-acting drug delivery domain, which has some of the very recent and precise activities listed for the clients to help them make better decisions in its report titled, Long-Acting Drug Delivery Technologies and Services Market, 2023-2035. To find answers to key decision-making question and to know further about the market forecast analysis, highlighting the likely growth of the long-acting drug delivery technologies and services market, for the time period 2023-2035. For additional details, please visit https://www.rootsanalysis.com/blog/long-acting-drug-delivery-technologies/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Digital Therapies: The “Digital Pills” of current generation As per United Nation’s report, the current global population stands at around 8 billion and expected to reach 9 billion by the end of 2030. This increase in population is accompanied with a rise in the incidence of several chronic disease indications. In fact, as per a report published by National Association of Chronic Disease Director, by 2030 this increase of the chronic condition would cost the US economy about USD 2 trillion. Furthermore, the lack of medical awareness and vulnerability in the medical infrastructure is believed to make the things more complicated in the coming future. Therefore, in order to cater this need, a number of stakeholders have come up with the innovative solution of digitizing the healthcare industry with next generation tools, such as artificial intelligence, digital therapies, telemedicine, electronic health records and others. It is worth noting that these next generation techniques have demonstrated significant potential to improve the quality of lives of individuals suffering from chronic conditions. What is Digital Therapeutic? Digital Therapeutics is one of the many new initiatives undertaken by the stakeholders to cater the growing need. As per Digital Therapeutics Alliance, digital therapeutics is a software-based intervention to patients to treat, manage or prevent a disease or disorder. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing motivational support and inculcating healthy lifestyle changes. Moreover, in order to be at par with the conventional medicines, several organizations have taken the initiative of validating their product in clinical trials for its safety and efficacy. In fact, the term “digital pills” has been coined due to its ability to compete against the conventional medicines/drugs. Furthermore, several organizations have undertaken key diverse initiatives in the field of digital therapies to support its growth as a new frontier in the healthcare sector. For instance, several organizations are focused on the development of prescription digital therapeutic solutions, wherein the product is prescribed by healthcare professionals or clinicians after confirmation of the eligibility of patients for using such solutions. In addition, to make digital therapeutics more engaging, these are currently being offered in a combination of software applications and others such as gaming solution, personal coach, and AI support. It is worth mentioning that the ease of use, personalized experience, accessibility, and convenience coupled with the COVID-19 pandemic, has popularized the digital therapeutics among the general population. In fact, countries, such as United States, Germany, UK, and others now have come up with their own laws to regulate the digital therapeutics among its population. For instance, in United States, the USFDA has implemented “Breakthrough Device Designation Program” for regularizing digital therapies as a medical intervention / solution for various indication. Likewise, UK have NHS based digital therapeutics database, wherein clinicians can refer for prescribing products and Germany has “Digital Health Act-2019”, for regularization of digital therapeutics. Bottom-Line Amidst growing competition, the availability of cutting-edge tools and technologies have emerged as a differentiating factor. This has caused many big pharma companies to actively expand their service portfolios, either through strategic acquisitions or entering into alliances with other digital therapeutic developers. Recent examples include AstraZeneca’s collaboration with digital therapeutics developer my health, wherein both the companies integrated their proprietary products for better outcome. You can also check out our report on digital therapies by visiting ‘digital health market ‘section. For additional details, please visit https://www.rootsanalysis.com/blog/digital-therapies-the-digital-pills/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Demand for Outsourcing Biologics Fill Finish Services The increasing demand for biologics has led to an increasing need for production capacity, which is characterized by high quality standards. Although, it is a challenging field, outsourcing has emerged as a promising segment, especially for drug product manufacturing and aseptic fill / finish operations. Despite being one of the crucial steps of all the steps involved in the production of biologics, fill finish is heavily outsourced activities in the pharmaceutical industry. Currently, it is estimated that more than 50% of the overall operations are outsourced to service providers. Service providers offering these services are using vials for filling of biologics. Of these, over 70% of service providers operate at clinical and commercial scales of operation. Of the players offering these services for biologics are headquartered in Asia-Pacific. More than 35% of these players are located in China. Further, of these, more than 40% players are well established players. Expansions have been witnessed by the industry, since 2013 to cater to the increasing need of their clients; of these, 55% expansions are associated with the establishment of new facility or adding area to the existing facility. Of global biologic fill finish capacity available in the facilities established by services providers is for filling of vials. Further, majority of capacity is available with service providers headquartered in Asia-Pacific. As projected by Roots Analysis, antibodies will have the highest share in this market. This trend is likely to continue in the future. In addition, majority of the market is likely to be driven by the filling of vials and syringes. More than 35% of these service providers are headquartered in Europe. Over 20% of these players were established before 1960 and 45% of the players were established after 2000. With outsourcing being increasingly accepted as a viable / beneficial business model and the anticipated growth in the biologics market, the opportunity for fill finish biopharmaceuticals service providers is expected to grow at a steady pace over the coming years. For additional details, please visit https://www.rootsanalysis.com/blog/demand-for-outsourcing-biologics-fill-finish/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

The Future of Dentistry: Dental 3D Printing 3D printing, also known as additive manufacturing, is a method of producing 3-dimensional objects layer-by-layer, using a computer aided design. Owing to its ability to print complex models using a wide range of materials, 3D printing has applications across various industries, including dental, aerospace, automotive, healthcare, food, fashion, mechanical engineering and other manufacturing industries. In recent years, the adoption of 3D printers has risen at a commendable pace, specifically in the dental industry. This is primarily due to the increasing scope of inhouse dental 3D printing, growth in digital dentistry business and rise in the demand for 3D printed products. 3D printing in dental industry is an advanced solution which produces high quality and more accurate dental products (including, crown and bridges, dentures, surgical guides and dental implants). Moreover, this process is time saving and economical for both the patients and dentists. What are the Key Advantages of Dental 3D Printers? The conventional dental product manufacturing methods are fraught with several challenges, including poor quality and accuracy of dental products, time-consuming printing processes and high cost of dental products. Dental 3D printing offers more treatment choices for both patients and clinicians in economical prices, while increasing the quality of care and services provided to the patients. Further, given that this is a digitalized process, the products manufactured using it can be easily customized (even the complex dental structures), and, therefore, offers more precise and accurate solutions for dental applications. Dental 3D Printing Technologies These printers employ various types of printing processes / technologies, including vat polymerization, polyjet printing, material extrusion and powder bed fusion process, to manufacture highly accurate restorations, orthodontic models, dentures, aligners, crowns, retainers, bridges, as well as surgical guides, from various types of materials, including resins, plastics, metals, ceramics and other materials. Dental 3D Printers: Current Market Landscape Presently, around 230 dental 3D printers are available for use across wide range of dental products; majority of these devices print crowns, bridges, dentures and working models. Further, more than 80% of the dental 3D printers use vat polymerization and powder bed fusion as printing process; of these, around 70% offer wavelength of 405 nm. Dental 3D Printers: Current Developer Landscape Currently, around 80 players are engaged in the manufacturing of dental 3D printers across the globe. The current market landscape is highly fragmented, featuring the presence of both new entrants and established players across key geographical regions; the majority of these players are based in Europe and Asia-Pacific. The below pasted donut chart, shows the distribution of dental 3D printer developers by company size and location of their headquarters. The Increasing Interest in this Field is also Reflected in Recent Partnership Activity Since 2018, partnership activity within the dental 3D printing domain has increased, with an annualized growth rate of 70.87%. Further, product integration agreements have captured a substantial share of the partnerships related to this domain, during the period of 2018-2022. This was followed by distribution agreements, which have captured a significant share of the partnerships inked in this domain. Further, the maximum number of partnerships in this domain was observed in 2021, followed by those signed in 2022. This rise in partnership activity in the last two years can be attributed to the increasing demand of dental 3D printers. Driven by the growing prevalence of dental diseases and rising demand for high quality dental products, the dental 3D printing market is anticipated to witness a steady growth in the foreseen future. For additional details, please visit https://www.rootsanalysis.com/blog/dental-3d-printing/ or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Bioavailability Enhancement Technologies A study conducted on terminated drug development projects revealed that majority of the drug candidates fail in early drug development phases, due to the problems associated with their pharmacokinetic profiles, ADME properties and toxicity-related issues. Moreover, it is a well-established fact that the systemic / local absorption and distribution of a therapeutic intervention is directly proportional to its bioavailability. In this context, it is also worth highlighting that more than 90% of new chemical entities (NCEs) developed by pharmaceutical companies and nearly 40% of the top-ranking oral drugs marketed in North America and Europe are insoluble in water and, hence, their low solubility can lead to deficient drug concentration, which further leads to in vivo failure. As a result, a large number of companies are now considering adopting various types of bioavailability enhancement technologies in order to ensure that their proprietary pharmacological product candidates are made bioavailable at optimal quantities at the desired site of action. However, in addition to being a time and cost intensive process, bioavailability enhancement is often fraught with several challenges and considering the expertise available with specialty service providers to improve the pharmacokinetic properties of novel molecules, drug developers are actively outsourcing their requirements. Diverse Landscape of Bioavailability Enhancement Technology and Service Providers During our research, we came across nearly 115 players, which claim to offer technologies and services for bioavailability enhancement of drug products / candidates. As per our analysis, North America and Europe, with the highest number of technology as well as service providers, have emerged as key hubs. Further, across all regions, majority of the companies are well established. Which Company has an Edge Over Other Companies? Several bioavailability enhancement service providers are constantly making efforts to expand current capabilities to enhance their respective product portfolios and comply to evolving industry benchmarks. Recent activity in Bioavailability Enhancement Market At present, the bioavailability enhancement technology and service providers are actively trying to consolidate their presence in this field by entering into strategic alliances, to meet the indubitably rising demand for effective therapeutics. Current Annual Demand for Bioavailability Technologies and Services Considering the concerns related to low solubility / permeability of certain marketed drugs and a large number of NCEs, the demand for bioavailability enhancement technologies and services is anticipated to rise in the future, with a CAGR of ~10%. Future Evolution of Bioavailability Enhancement Services Market As mentioned earlier, owing to the high costs and technical expertise associated with formulation development process, stakeholders in the industry are likely to rely more on specialty service providers. Additionally, driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is likely to grow at CAGR of ~11%, till 2035 Further, the estimated market opportunity is expected to be well distributed across different types of drug classes, dosage forms and key geographical regions Technology Evaluation Framework With the market evolving at a steady pace, emerging players need to incorporate innovative bioavailability enhancement technologies to augment their service portfolio and surpass the competition. To address these concerns, we have proposed a proprietary framework. Technology evaluation framework provides a value addition matrix for bioavailability enhancement approaches currently employed by industry stakeholders. For additional details, please visit https://www.rootsanalysis.com/blog/bioavailability-enhancement-technologies/ or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com